UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 196

Sortiert nach

Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines

International journal of oncology, 2017-12, Vol.51 (6), p.1860-1868

2017

Volltextzugriff (PDF)

Development of a multi‐recombinase polymerase amplification assay for rapid identification of COVID‐19, influenza A and B

Journal of medical virology, 2023-01, Vol.95 (1), p.e28139-n/a

2023

Volltextzugriff (PDF)

RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells

Current cancer drug targets, 2023-01, Vol.23 (2), p.103

2023

Volltextzugriff (PDF)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.17588359211006957-17588359211006957

2021

Volltextzugriff (PDF)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

Journal of experimental & clinical cancer research, 2020-09, Vol.39 (1), p.1-18, Article 198

2020

Volltextzugriff (PDF)

Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma

Hepatobiliary & pancreatic diseases international, 2021-12, Vol.20 (6), p.530-534

2021

Volltextzugriff (PDF)

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Engineering (Beijing, China), 2019-10, Vol.5 (5), p.940-947

2019

Volltextzugriff (PDF)

Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets

Cancer letters, 2007-11, Vol.257 (2), p.157-164

2007

Volltextzugriff (PDF)

The viral distribution and pathological characteristics of BALB/c mice infected with highly pathogenic Influenza H7N9 virus

Virology journal, 2021-11, Vol.18 (1), p.237-237, Article 237

2021

Volltextzugriff (PDF)

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

Cancer Research and Treatment, 2020, 52(3), , pp.973-986

2020

Volltextzugriff (PDF)

An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells

Oncology reports, 2016-11, Vol.36 (5), p.2763-2770

2016

Volltextzugriff (PDF)

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

Therapeutic Advances in Medical Oncology, 2020, Vol.12, p.1758835920920069-1758835920920069

2020

Volltextzugriff (PDF)

Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma

World journal of gastroenterology : WJG, 2016-05, Vol.22 (18), p.4538-4546

2016

Volltextzugriff (PDF)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Frontiers in oncology, 2019-12, Vol.9, p.1377-1377

2019

Volltextzugriff (PDF)

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Journal of experimental & clinical cancer research, 2016-04, Vol.35 (70), p.70, Article 70

2016

Volltextzugriff (PDF)

Host proteins interact with viral elements and affect the life cycle of highly pathogenic avian influenza A virus H7N9

Heliyon, 2024-04, Vol.10 (7), p.e28218-e28218, Article e28218

2024

Volltextzugriff (PDF)

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Molecular oncology, 2014-05, Vol.8 (3), p.469-482

2014

Volltextzugriff (PDF)

Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer

Biochimica et biophysica acta. Reviews on cancer, 2020-12, Vol.1874 (2), p.188425, Article 188425

2020

Volltextzugriff (PDF)

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

Drug discovery today, 2021-08, Vol.26 (8), p.1857-1874

2021

Volltextzugriff (PDF)

Novel pathogenic characteristics of highly pathogenic avian influenza virus H7N9: viraemia and extrapulmonary infection

Emerging microbes & infections, 2020-01, Vol.9 (1), p.962-975

2020

Volltextzugriff (PDF)

Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma

Acta pharmacologica Sinica, 2008-02, Vol.29 (2), p.239-244

2008

Volltextzugriff (PDF)

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements

Frontiers in microbiology, 2018-11, Vol.9, p.2724-2724

2018

Volltextzugriff (PDF)

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells

Molecular cancer, 2011-07, Vol.10 (1), p.82-82, Article 82

2011

Volltextzugriff (PDF)

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

Biochimica et biophysica acta. Reviews on cancer, 2020-04, Vol.1873 (2), p.188360-188360, Article 188360

2020

Volltextzugriff (PDF)

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Drug discovery today, 2021-01, Vol.26 (1), p.106-121

2021

Volltextzugriff (PDF)

1 – 25 von 196

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(182)

Publikationsform

Artikel
(193)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Humans
(79)
Life Sciences & Biomedicine
(77)
Animals
(47)
Oncology
(33)
Mice
(29)
Female
(24)
Male
(23)
Cell Line, Tumor
(22)
Middle Aged
(17)
Receptor Tyrosine Kinase
(16)
Mice, Inbred Balb C
(14)
Adult
(13)
Transfection
(13)
Receptor Protein-Tyrosine Kinases - Metabolism
(12)
Pharmacology & Pharmacy
(11)
Proteins
(11)
Apoptosis - Drug Effects
(10)
Cell Line
(10)
Receptor Protein-Tyrosine Kinases - Genetics
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines

Development of a multi‐recombinase polymerase amplification assay for rapid identification of COVID‐19, influenza A and B

RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets

The viral distribution and pathological characteristics of BALB/c mice infected with highly pathogenic Influenza H7N9 virus

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Host proteins interact with viral elements and affect the life cycle of highly pathogenic avian influenza A virus H7N9

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

Novel pathogenic characteristics of highly pathogenic avian influenza virus H7N9: viraemia and extrapulmonary infection

Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Suchergebnisse filtern